

1 **NATIONAL INSTITUTE FOR HEALTH AND CARE**
2 **EXCELLENCE**

3 **Guideline scope update**

4 **Diabetes (type 1 and type 2) in children and young people:**
5 **diagnosis and management (update)**

6 This guideline will update the NICE guideline on diabetes (type 1 and type 2) in
7 children and young people (NG18). The update will look at medicines that can be
8 used to treat type 2 diabetes in combination with metformin or, as an alternative if
9 metformin is not tolerated.

10 **March 2023 addition**

11 Following stakeholder consultation, this guideline update will now also look at
12 continuous glucose monitoring for children and young people with type 2 diabetes.

13 The update will be developed using the methods and processes outlined in
14 [developing NICE guidelines: the manual](#).

15 This update may also be used to update the [NICE quality standard for diabetes in](#)
16 [children and young people](#).

17 **1 Why the update is needed**

18 New evidence that could affect recommendations was identified through the
19 surveillance process. Topic experts, including those who helped to develop the
20 existing guideline, advised NICE on whether areas should be updated or new areas
21 added. Full details are set out in the [surveillance review decision](#).

22 **2 Who the update is for**

23 This guideline is for:

- 24 • healthcare professionals who care for children and young people with type 2
25 diabetes
- 26 • commissioners and providers of NHS-funded healthcare services
- 27 • children and young people with type 2 diabetes, and their families and carers.
- Diabetes (type 1 and type 2) in children and young people: NICE guideline (May 2022)

1 NICE guidelines cover health and care in England. Decisions on how they apply in
2 other UK countries are made by ministers in the [Welsh Government](#), [Scottish](#)
3 [Government](#) and [Northern Ireland Executive](#).

4 **Equality considerations**

5 NICE has carried out an [equality impact assessment](#) during scoping. The
6 assessment:

- 7 • lists equality issues identified, and how they have been addressed
- 8 • explains why any groups are excluded from the scope.

9 The guideline will look at inequalities relating to age, disability, race, ethnicity,
10 religion and belief.

11 **3 What the update will cover**

12 **3.1 Who is the focus?**

13 **Groups that will be covered**

- 14 • Children and young people aged under 18 with type 2 diabetes.

15 **3.2 Settings**

16 **Settings that will be covered**

- 17 • All settings where NHS care is provided.

18 **3.3 Activities, services or aspects of care**

19 **Key areas that will be covered in this update**

20 We will look at evidence in the areas below when developing this update. We will
21 consider making new recommendations or updating existing recommendations in
22 these areas only.

- 23 1 Medicines that can be used to treat type 2 diabetes in children and young
24 people in combination with metformin, or as an alternative if metformin is not
25 tolerated.

1 2 From March 2023: Continuous glucose monitoring for children and young
2 people with type 2 diabetes.

3

4 Note that guideline recommendations for medicines will normally fall within licensed
5 indications; exceptionally, and only if clearly supported by evidence, use outside a
6 licensed indication may be recommended. The guideline will assume that prescribers
7 will use a medicine's summary of product characteristics to inform decisions made
8 with individual patients.

9 **Changes to the guideline**

10 For the [section on metformin for children and young people with type 2 diabetes](#), we
11 will review the evidence for medicines that can be used in combination with
12 metformin or if metformin is not tolerated, and consider making new
13 recommendations or updating the existing recommendation.

14 From March 2023: Following stakeholder consultation, we will also consider making
15 recommendations regarding continuous glucose monitoring for children and young
16 people with type 2 diabetes.

17 For all other sections of the guideline, there will be no evidence review and we will
18 retain the existing recommendations.

19 Recommendations in areas that are being retained may be edited to ensure that they
20 meet current editorial standards and reflect the current policy and practice context.

21 **NICE guidance related to this update**

22 **Published**

- 23 • [Type 2 diabetes in adults: management](#) (2022) NICE guideline NG28
- 24 • [Diabetic foot problems: prevention and management](#) (2015) NICE guideline NG20
- 25 • [Type 2 diabetes: prevention in people at high risk](#) (2012) NICE guideline PH38
- 26 • [Type 2 diabetes prevention: population and community-level interventions](#) (2011)
27 NICE guideline PH35
- 28 • [Weight management: lifestyle services for overweight or obese children and](#)
29 [young people](#) (2013) NICE guideline PH47
- 30 • [Physical activity for children and young people](#) (2009) NICE guideline PH17
Diabetes (type 1 and type 2) in children and young people: NICE guideline (May 2022)

- 1 • [Obesity prevention](#) (2006) NICE guideline CG43
- 2 • [Dental checks: intervals between oral health reviews](#) (2004) NICE clinical
- 3 guideline CG19

4 **In development**

- 5 • [Sotagiflozin for treating type 2 diabetes](#) [ID1657]. NICE technology appraisal
- 6 guidance. Publication date to be confirmed.
- 7 • [Tirzepatide for treating type 2 diabetes](#) [ID3938]. NICE technology appraisal
- 8 guidance. Publication date to be confirmed.

9 **NICE guidance about the experience of people using NHS services**

10 NICE has produced the following guidance on the experience of people using the
11 NHS. This guideline will not include additional recommendations on these topics
12 unless there are specific issues related to type 2 diabetes in children and young
13 people.

- 14 • [Babies, children and young people's experience of healthcare](#) (2021) NICE
- 15 guideline NG204
- 16 • [Shared decision making](#) (2021) NICE guideline NG197
- 17 • [Medicines optimisation](#) (2015) NICE guideline NG5

18 **3.4 Economic aspects**

19 We will take economic aspects into account when making recommendations. We will
20 develop an economic plan that states for each review question (or key area in the
21 scope) whether economic considerations are relevant, and if so whether this is an
22 area that should be prioritised for economic modelling and analysis. We will review
23 the economic evidence and carry out economic analyses, using a NHS, public sector
24 and other perspectives, as appropriate.

25 **3.5 Key issues and draft questions**

26 While writing the scope for this updated guideline, we have identified the following
27 key issue and draft question related to it:

- 28 1 Treatment for type 2 diabetes in children and young people

1 1.1 What is the clinical effectiveness, cost effectiveness and acceptability
2 of pharmacological treatments for improving glycaemic control in children
3 and young people with type 2 diabetes, in combination with metformin or,
4 as an alternative if metformin is not tolerated, compared with usual care
5 (metformin alone)?

6 The key issue and draft question will be used to develop more detailed review
7 questions, which guide the systematic review of the literature.

8 **3.6 Main outcomes**

9 The main outcomes that may be considered when searching for and assessing the
10 evidence are:

- 11 • glycaemic control
- 12 • any adverse effects of the medicines used
- 13 • health-related quality of life (assessed by validated questionnaire), for example
14 diabetes-specific health-related quality of life
- 15 • complications of diabetes
- 16 • mortality
- 17 • patient satisfaction
- 18 • intermediate outcomes (including disease management goals such as blood
19 pressure, lipid profile and BMI)
- 20 • use of health services (including hospitalisation, A&E attendance, and financial
21 barriers to care)
- 22 • patient-reported outcomes (including psychological well-being [WHO-5], diabetes
23 distress [PAID], depression [PHQ-9], and activities of daily living).

24 **4 NICE quality standards**

25 **NICE quality standards that may need to be revised or updated when this**
26 **guideline is published**

- 27 • [Diabetes in children and young people](#) (2016) NICE quality standard 125.

28

1 Further information

This is the final scope, which takes into account comments from registered stakeholders during consultation.

The guideline is expected to be published in May 2023.

You can [follow progress of the guideline](#).

Our website has information about how [NICE guidelines](#) are developed.

2 © NICE 2023. Subject to [Notice of rights](#).